Cutera Inc.
45
0
1
37
Key Highlights
Risk & Performance
Pipeline Risk Assessment
Pipeline Risk Assessment
Based on historical performance
Low Risk
Score: 25/100
11.1%
5 terminated/withdrawn out of 45 trials
88.1%
+1.6% vs industry average
2%
1 trials in Phase 3/4
97%
36 of 37 completed trials have results
Key Signals
Enrollment Performance
Analytics
Activity Timeline
Global Presence
Clinical Trials (45)
Facial Papules in Frontal Fibrosing Alopecia (FFA)
Role: collaborator
A Post Market Device Study for the Treatment of Acne
Role: lead
A Device Study for the Treatment of Acne
Role: lead
Split-tattoo Study Comparing the Safety and Efficacy of 670nm Picosecond Laser Versus 755 nm for Tattoo Removal
Role: lead
Multi-Wavelength Laser Tattoo Removal Pivotal Study
Role: lead
Evaluation of the Cutera Enlighten™ Laser With Micro-Lens Array (MLA) Handpiece Attachment
Role: lead
Ultrasound Device for Hair Removal
Role: lead
A Study of a Novel Multi-Wavelength Laser for Tattoo Removal
Role: lead
Radio Frequency (RF) Device for Reduction in Size of Localized Areas of the Body
Role: lead
Multi-Center Pilot Study of truSculpt Device
Role: lead
Multi-Center, Clinical Evaluation of the Cutera Secret RF Device
Role: lead
Pilot Study of Multi-wavelength Laser for Tattoo Removal
Role: lead
Study of a Novel Laser for Skin Rejuvenation
Role: lead
Open-label, Prospective, Multicenter Study to Evaluate the Cutera Excel V™ Laser and a Micro-Lens Array Attachment
Role: lead
Pivotal Study of the Cutera truSculpt Radiofrequency Device for Wrinkle Reduction
Role: lead
Multi-Center Pilot Study of Cutera truSculpt Device
Role: lead
A Single-Center Open-Label Study of 1064 nm for Nonablative Skin Rejuvenation
Role: lead
Evaluation of Cutera Excel V™ Laser With Green Genesis and Micro-Lens Array (MLA)Attachment
Role: lead
Study of a Novel Microlens Array Device for Skin Rejuvenation
Role: lead
enLighten Laser With MLA Handpiece for Treatment of Moderate and Severe Acne Scars
Role: lead